A previous study has shown that VCAM1 is highly expressed in the aortic valves of diabetic/atherosclerotic ApoE-deficient mice and is considered a potential target for nanocarriers developed to block the progression of AS [19]. This evidence concerns the gene APOE and aortic valve stenosis.